Oral Psoriasis Drug Landscape
As of 2026-11-14, BMS’s Sotyktu and J&J’s Icotyde had US psoriasis approvals; Takeda’s zasocitinib was under Priority Review as a regulatory challenger.
Alumis reiterated on 2026-11-12 that 54% achieved PASI 100 at Week 48 in ONWARD3 with envudeucitinib; this extension result is not a head-to-head comparison.
Takeda announced on 2026-09-14 that the FDA target action window for zasocitinib was Q1 2027; that decision could change competition among approved oral drugs.
Oral systemic drugs for plaque psoriasis, covering TYK2, IL-23R, PDE4 and A3 receptor approaches. PASI results from different trials are not an efficacy league table.
Competitive landscape
| Asset | Company | Mechanism / route | Stage | Indication | Trial identifier | Deal | Latest development | Source |
|---|---|---|---|---|---|---|---|---|
| Sotyktu / deucravacitinib | Bristol Myers SquibbUS | Allosteric TYK2 inhibitorOral | US approved | Adult plaque psoriasis | — | — | Approved TYK2 benchmark | packageinserts.bms.com |
| Icotyde / icotrokinra | Johnson & JohnsonUS | IL-23 receptor antagonist peptideOral | US approved | Moderate-to-severe plaque psoriasis, age 12+, at least 40 kg | — | — | FDA approval 2026-03-17; four trials, 2,500 participants; company release dated March 18 | fda.gov |
| zasocitinib / TAK-279 | TakedaJapan | TYK2 inhibitorOral | FDA Priority Review | Moderate-to-severe plaque psoriasis | NCT06973291 | — | Head-to-head LATITUDE Atlas versus deucravacitinib; FDA target Q1 2027 | takeda.comtakeda.com.cn |
| envudeucitinib | AlumisUS | TYK2 inhibitorOral | Phase 3 results; filing planned | Moderate-to-severe plaque psoriasis | — | — | Week 48 PASI 100: 54%; NDA planned Q4 2026 | investors.alumis.comalumis.com |
| Otezla / apremilast | AmgenUS | PDE4 inhibitorOral | US approved | Plaque psoriasis; label-specific age and weight requirements | — | — | Established oral comparator, distinct from TYK2 | dailymed.nlm.nih.gov |
| piclidenoson / CF101 | Can-FiteIsrael | A3 adenosine receptor agonistOral | Phase 3 on company pipeline | Plaque psoriasis | NCT06643260 | — | Investigational mechanism; unreported outcomes are not assumed | canfite.com |
Taiwan and Asia
Japan’s Takeda anchors the Asian coverage, with global Phase 3 and a direct comparison against deucravacitinib. The landscape also compares oral PDE4 and IL-23 receptor approaches; injectable products and distribution rights are outside this development field.